Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

Management

Management

Jim Baker

Senior Vice President, Corporate Affairs

Percy Carter, MBA, Ph.D.

Chief Scientific Officer

Debbie Durso-Bumpus

Chief People Officer

Kate Haviland

President and Chief Executive Officer

Becker Hewes, M.D.

Chief Medical Officer

Helen Ho, Ph.D.

Chief Business Officer

Mike Landsittel

Chief Financial Officer

Philina Lee, Ph.D.

Chief Commercial Officer

Tracey L. McCain, Esq.

Executive Vice President, Chief Legal and Compliance Officer

Georg P. Meyer, M.D.

Senior Vice President, Head of International

Fouad Namouni, M.D.

President, Research & Development

Christina Rossi

Chief Operating Officer

Sherwin Sattarzadeh

Senior Vice President, Strategic Operations